Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 71.60
Bid: 70.20
Ask: 73.00
Change: 0.00 (0.00%)
Spread: 2.80 (3.989%)
Open: 71.60
High: 0.00
Low: 0.00
Prev. Close: 71.60
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Liquidity Agreement and Total Voting Rights

1 Sep 2021 11:30

RNS Number : 3868K
Novacyt S.A.
01 September 2021
 

Novacyt S.A.

 

("Novacyt" or the "Company")

 

Liquidity Agreement Monthly Update and Total Voting Rights

 

Paris, France and Camberley, UK - 1 September 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the "Liquidity Agreement"). The Liquidity Agreement is governed by French law and is further summarised in the 'notes for editors' section below.

 

During the period from 1 August to 31 August 2021, Invest Securities purchased 3,896 ordinary shares at a maximum price of €5.00 and a minimum price of €3.40 and sold 4,646 ordinary shares at a maximum price of €5.03 and a minimum price of €3.49 under the Liquidity Agreement. The total number of ordinary shares in the Company, which are held in treasury as at close of business on 31 August 2021, is 11,294.

 

Total Voting Rights

 

The total number of ordinary shares in the Company is 70,626,248. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.

 

For further information, please refer to www.novacyt.com or contact:

 

Novacyt SA

Graham Mullis, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com/ y.petit@allegrafinance.com

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / Alex.Shaw@fticonsulting.com

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

 

For more information please refer to the website: www.novacyt.com

 

Further information on the Liquidity Agreement

On 12 September 2016, the Company and Invest Securities entered into the Liquidity Agreement pursuant to which Invest Securities provides liquidity services in relation to the ordinary shares to the Company. Invest Securities may purchase ordinary shares on behalf of the Company under the agreement, subject to approval from Shareholders as to the price at which ordinary shares can be brought back and the aggregate amount that the Company may provide to Invest Securities to purchase such ordinary shares.

 

Shareholder approval was granted at the Shareholders' meeting held on 29 September 2020 for the purchase of ordinary shares by Invest Securities under the agreement at a maximum purchase price per ordinary shares of €12.00 for an aggregate maximum purchase price of €200,000 and for 18 months from the date of the approval. Under the agreement, Invest Securities must act completely independently of the Company and the Company must not communicate with the employees of Invest Securities who are responsible for performing the agreement. Invest Securities is paid €10,000 per annum for its services under the liquidity agreement. The agreement has an initial term of two years, with a rolling extension of one year thereafter. The agreement can be terminated by either party at the end of each such period subject to two months' prior notice. The Liquidity Agreement is governed by French law. Ordinary shares purchased by Invest Securities are either cancelled or held as treasury shares (which are non-voting and do not rank for dividends).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRKFLBBFKLEBBX
Date   Source Headline
13th Jul 20207:00 amRNSHalf-Year Trading Update
3rd Jul 20204:41 pmRNSSecond Price Monitoring Extn
3rd Jul 20204:35 pmRNSPrice Monitoring Extension
1st Jul 20204:48 pmRNSCorrection: Liquidity Agrmnt & Total Voting Rights
1st Jul 202011:15 amRNSLiquidity Agreement and Total Voting Rights
30th Jun 20203:30 pmRNSPublication of Annual Report
29th Jun 20204:41 pmRNSSecond Price Monitoring Extn
29th Jun 20204:36 pmRNSPrice Monitoring Extension
29th Jun 20202:06 pmRNSSecond Price Monitoring Extn
29th Jun 20202:00 pmRNSPrice Monitoring Extension
25th Jun 20204:42 pmRNSSecond Price Monitoring Extn
25th Jun 20204:36 pmRNSPrice Monitoring Extension
18th Jun 20207:00 amRNSThree new products to support COVID-19 testing
15th Jun 20202:05 pmRNSSecond Price Monitoring Extn
15th Jun 20202:00 pmRNSPrice Monitoring Extension
3rd Jun 20201:30 pmRNSDirector/PDMR Shareholding
3rd Jun 20207:00 amRNSEarly settlement of term loan
2nd Jun 20207:00 amRNSCoronavirus update
1st Jun 202012:15 pmRNSTotal Voting Rights
26th May 20206:15 pmRNSDirector/PDMR Shareholding
18th May 20204:41 pmRNSSecond Price Monitoring Extn
18th May 20204:36 pmRNSPrice Monitoring Extension
18th May 20202:06 pmRNSSecond Price Monitoring Extn
18th May 20202:00 pmRNSPrice Monitoring Extension
18th May 202011:05 amRNSSecond Price Monitoring Extn
18th May 202011:00 amRNSPrice Monitoring Extension
18th May 20209:00 amRNSDirector/PDMR Shareholding
14th May 20204:41 pmRNSSecond Price Monitoring Extn
14th May 20204:36 pmRNSPrice Monitoring Extension
14th May 20207:00 amRNSFinal Results for the year ended 31 December 2019
4th May 20201:45 pmRNSLiquidity Agreement and Total Voting Rights
29th Apr 20207:00 amRNSCOVID-19 update and notification of final results
27th Apr 202011:06 amRNSSecond Price Monitoring Extn
27th Apr 202011:00 amRNSPrice Monitoring Extension
27th Apr 20209:05 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSContract with UK Department of Health
22nd Apr 202011:06 amRNSSecond Price Monitoring Extn
22nd Apr 202011:00 amRNSPrice Monitoring Extension
22nd Apr 20209:05 amRNSSecond Price Monitoring Extn
22nd Apr 20209:00 amRNSPrice Monitoring Extension
15th Apr 20204:41 pmRNSSecond Price Monitoring Extn
15th Apr 20204:36 pmRNSPrice Monitoring Extension
15th Apr 20204:15 pmRNSManufacturing and R&D update for COVID-19 test
15th Apr 20202:05 pmRNSSecond Price Monitoring Extn
15th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 202011:05 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
14th Apr 202011:06 amRNSSecond Price Monitoring Extn
14th Apr 202011:01 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.